Literature DB >> 16844716

Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology.

Estibaliz Capetillo-Zarate1, Matthias Staufenbiel, Dorothee Abramowski, Christian Haass, Angelika Escher, Christine Stadelmann, Haruyasu Yamaguchi, Otmar D Wiestler, Dietmar Rudolf Thal.   

Abstract

The amyloid beta-protein (Abeta) is the main component of Alzheimer's disease-related senile plaques. Although Abeta is associated with the development of Alzheimer's disease, it has not been shown which forms of Abeta induce neurodegeneration in vivo and which types of neurons are vulnerable. To address these questions, we implanted DiI crystals into the left frontocentral cortex of APP23 transgenic mice overexpressing mutant human APP (amyloid precursor protein gene) and of littermate controls. Traced commissural neurons in layer III of the right frontocentral cortex were quantified in 3-, 5-, 11- and 15-month-old mice. Three different types of commissural neurons were traced. At 3 months of age no differences in the number of labelled commissural neurons were seen in APP23 mice compared with wild-type mice. A selective reduction of the heavily ramified type of neurons was observed in APP23 mice compared with wild-type animals at 5, 11 and 15 months of age, starting when the first Abeta-deposits occurred in the frontocentral cortex at 5 months. The other two types of commissural neurons did not show alterations at 5 and 11 months. At 15 months, the number of traced sparsely ramified pyramidal neurons was reduced in addition to that of the heavily ramified neurons in APP23 mice compared with wild-type mice. At this time Abeta-deposits were seen in the neo- and allocortex as well as in the basal ganglia and the thalamus. In summary, our results show that Abeta induces progressive degeneration of distinct types of commissural neurons. Degeneration of the most vulnerable neurons starts in parallel with the occurrence of the first fibrillar Abeta-deposits in the neocortex, that is, with the detection of aggregated Abeta. The involvement of additional neuronal subpopulations is associated with the expansion of Abeta-deposition into further brain regions. The vulnerability of different types of neurons to Abeta, thereby, is presumably related to the complexity of their dendritic morphology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16844716     DOI: 10.1093/brain/awl176

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  24 in total

1.  Transgenic expression of intraneuronal Aβ42 but not Aβ40 leads to cellular Aβ lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology.

Authors:  Dorothee Abramowski; Sabine Rabe; Ajeet Rijal Upadhaya; Julia Reichwald; Simone Danner; Dieter Staab; Estibaliz Capetillo-Zarate; Haruyasu Yamaguchi; Takaomi C Saido; Karl-Heinz Wiederhold; Dietmar Rudolf Thal; Matthias Staufenbiel
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+).

Authors:  Francisco J Gómez; Pabla Aguirre; Christian Gonzalez-Billault; Marco T Núñez
Journal:  J Neural Transm (Vienna)       Date:  2010-10-02       Impact factor: 3.575

3.  Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life.

Authors:  Ganesh M Shankar; Malcolm A Leissring; Anthony Adame; Xiaoyan Sun; Edward Spooner; Eliezer Masliah; Dennis J Selkoe; Cynthia A Lemere; Dominic M Walsh
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

4.  A novel approach for characterization of cathepsin D protease and its effect on tau and β-amyloid proteins.

Authors:  Mazhar Malik; Michael D Fenko; Ashfaq M Sheikh; Guang Wen; Xiaohong Li
Journal:  Neurochem Res       Date:  2011-01-26       Impact factor: 3.996

Review 5.  Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.

Authors:  Gunnar K Gouras; Davide Tampellini; Reisuke H Takahashi; Estibaliz Capetillo-Zarate
Journal:  Acta Neuropathol       Date:  2010-03-31       Impact factor: 17.088

6.  Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease.

Authors:  Harshvardhan Rolyan; Ann Caroline Feike; Ajeet Rijal Upadhaya; Andreas Waha; Tom Van Dooren; Christian Haass; Gerd Birkenmeier; Claus U Pietrzik; Fred Van Leuven; Dietmar Rudolf Thal
Journal:  J Neural Transm (Vienna)       Date:  2011-01-06       Impact factor: 3.575

7.  Early hyperactivity in lateral entorhinal cortex is associated with elevated levels of AβPP metabolites in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Wenjin Xu; Shane Fitzgerald; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Exp Neurol       Date:  2014-12-12       Impact factor: 5.330

Review 8.  Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease.

Authors:  Natalia A Stefanova; Oyuna S Kozhevnikova; Anton O Vitovtov; Kseniya Yi Maksimova; Sergey V Logvinov; Ekaterina A Rudnitskaya; Elena E Korbolina; Natalia A Muraleva; Nataliya G Kolosova
Journal:  Cell Cycle       Date:  2014-02-17       Impact factor: 4.534

9.  Pathology of clinical and preclinical Alzheimer's disease.

Authors:  Dietmar Rudolf Thal; Christine von Arnim; W Sue T Griffin; Haruyasu Yamaguchi; Robert E Mrak; Johannes Attems; Ajeet Rijal Upadhaya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

10.  Accumulation of intraneuronal β-amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses.

Authors:  Reisuke H Takahashi; Estibaliz Capetillo-Zarate; Michael T Lin; Teresa A Milner; Gunnar K Gouras
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.